On August 18, Kexon Pharmaceuticals announced that the Miboteco Infliximab biosimilar drug introduced by the company was recently approved for marketing by the Thai Food and Drug Administration. Injectable infliximab was approved for marketing by the National Drug Administration in 2021. It is the first infliximab biosimilar drug approved for marketing in China. It is used to treat rheumatoid arthritis, ankylosing spondylitis, psoriatic disease, Crohn's disease, fistulatory Crohn's disease, and adult ulcerative colitis in adults and children aged 6 and above.

On August 18, Kexon Pharmaceuticals announced that the Miboteco Infliximab biosimilar drug introduced by the company was recently approved for marketing by the Thai Food and Drug Administration. Injectable infliximab was approved for marketing by the National Drug Administration in 2021. It is the first infliximab biosimilar drug approved for marketing in China. It is used to treat rheumatoid arthritis, ankylosing spondylitis, psoriatic disease, Crohn's disease, fistulatory Crohn's disease, and adult ulcerative colitis in adults and children aged 6 and above.